Expanded access. Reduced burden. One platform.

Why

6,000+

choose Inato

Bring breakthroughs to your community

Apply for top-sponsor trials that match your site’s strengths, boosting patient access.

Reduce burden for
your team

Simplify feasibility, streamline communication, and reduce repetitive tasks so your team can focus on patients, not paperwork.

Enhance trial performance

From early planning to AI-powered pre-screening, Inato equips your site with the tools to drive enrollment and deliver results.

Our Platform

Shape your site’s trial pipeline, highlight its unique strengths, and easily apply for studies with top sponsors, all while reducing burden.

Our platform simplifies time-consuming processes, so you can spend your time on what matters: patients.

Learn more

Dashboard listing ongoing clinical trials including Heights Pharma Phase 3 for Asthma, Golden Elk Pharmaceuticals Phase 4 for SCLC, Bioclinical Pharma Phase II/III DLE, PharmaCorp Phase III Ulcerative Colitis, and Vaxcorp Phase 3 HPV.

Text encouraging adding diversity data to stand out to sponsors, with cards showing team speaks Spanish and PI identifies as Hispanic or Latino.

Notification stating selection for Heights Pharma - Phase 3 Brinkamab asthma trial with shield and checkmark icon.

List of five patients with icons and status buttons: Patients 1, 2, and 3 have green 'To screen' buttons with check marks; Patient 4 is highlighted with a purple 'To review' button and cursor pointer; Patient 5 has a gray 'Failed' button with an x mark.

How we do it

Explore a faster and easier way to connect with sponsors, get selected, and enroll the right patients.

Charts showing US patient population demographics and barriers to recruitment with comparison between US and Ex-US, plus treatment options impact and site comments on trial visit challenges.

Pie chart showing US patient population by race: Hispanic 50%, White 26%, Black 19%, Asian 3%, Other 2%.

Comparison cards for two clinical research sites: Abbott Northwestern Hospital led by Oscar G. Guttierez in Vineland, NJ, with 20 patients IVC, 6 PI trials in NSCLC, and 100% requirements met; and Applied Clinical Research led by Alexandra Brown, M.D. in Miami, FL, with 3 patients IVC, 4 trials in NSCLC, and 80% requirements met.

Chat interface suggesting three best clinical trial sites: Abbott Northwestern Hospital, Applied Clinical Research, and Clinical Research, with explanation of diversity and speed benefits.

Patient pre-screening table for Phase 3 Brinkamab severe asthma study showing six patients with their prescreening percentages and status: three to screen with 80-92%, two failed with 20-30%, and one to review at 10%.

Line chart showing a steady increase in patients pre-screened from December 29 to March 13, reaching a total of 35 patients.

Text highlighting top criteria for ineligibility as any other active disease or condition interfering with asthma assessment, with 31 patients excluded.

01

Early planning

Express early interest for trials that fit your patient needs and site interests. Your insights help shape study design and put your site ahead of the curve.

02

AI site selection

Showcase what makes your site stand out. Our platform highlights your strengths to sponsors, helping you get noticed and selected.

03

AI patient pre‑screening

Spend less time reviewing charts and more time enrolling. Our AI technology quickly and securely identifies eligible patients to accelerate review times and boost enrollment.

One platform to power trial success

Inato’s features are designed to work in sync, helping your site plan early, get selected faster, and enroll confidently, all while reducing burden for your staff and helping you focus on what matters: patients.

Request a demo